More Trump drug pricing deals, GSK speeds up development of mRNA flu vaccine, and other biotech news ...

Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for ...

The federal spending bill has an important provision for researchers, and Trump announced more MFN deals with pharma firms.

An NIH proposal to cap the number of research grants investigators can receive has drawn a mixed reception, the agency says.

GLP-1 drugs are almost single-handedly forcing employers to reconsider how they pay for their workers’ care.

President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.

There has been a wealth of new treatment available” for migraine prevention, said a co-author of new guidelines released ...

A drug patent case involving Amgen is being closely watched given its potential implications for pharmaceutical patent deals ...